Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Abstract Text:

R M M Cleijsen,M E van de Ende,F P Kroon,F Verduyn Lunel,P P Koopmans,L Gras,F de Wolf,D M Burger,R M M Cleijsen,M E van de Ende,F P Kroon,F Verduyn Lunel,P P Koopmans,L Gras,F de Wolf,D M Burger,

BACKGROUND: Therapeutic drug monitoring (TDM) is being applied for a number of antiretroviral agents. Little is known about the use of TDM for atazanavir. METHODS: This is a retrospective cohort analysis on the use of TDM of atazanavir at three clinical sites in The Netherlands. Patients were divided into three groups: (i) all patients with evaluable data of plasma atazanavir concentrations and its relationship with hyperbilirubinaemia; (ii) patients who started atazanavir without documented evidence of protease inhibitor (PI) mutations; (iii) patients who started atazanavir with documented evidence of PI mutations. The genotypic inhibitory quotient (GIQ) was calculated by dividing the mean atazanavir plasma trough concentration by the number of PI mutations. RESULTS: A total of 108 patients were included; 70 (65.8%) were using atazanavir/ritonavir (300/100 mg once daily). No significant relationship was observed between atazanavir plasma trough concentration and antiviral response in patients starting atazanavir without PI mutations (group 2; n = 82). In contrast, a significant relationship was observed between atazanavir GIQ and treatment response in patients starting atazanavir while having PI mutations (group 3; n = 26). The cut-off value for GIQ most predictive of virological failure was 0.23 mg/L/mutation: patients (n = 8) with a GIQ equal to or below this value had 50% virological failure whereas patients (n = 18) with a GIQ above 0.23 mg/L/mutation had only 11% virological failure (chi(2): P = 0.030). Atazanavir plasma trough concentrations were significantly related with the occurrence of increased total bilirubin concentrations. CONCLUSIONS: TDM of atazanavir might be beneficial for patients with documented PI resistance or patients with hyperbilirubinaemia.

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Publishing Authors By Initials

RM Cleijsen,ME van de Ende,FP Kroon,FV Lunel,PP Koopmans,L Gras,F de Wolf,DM Burger,RM Cleijsen,ME van de Ende,FP Kroon,FV Lunel,PP Koopmans,L Gras,F de Wolf,DM Burger,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of antimicrobial chemotherapy

VOLUME: 60

Page Numbers: 897-900

Journal Abbreviation: J. Antimicrob. Chemother.

ISSN: 0305-7453

DAY: 17

MONTH: 08

YEAR: 2007

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7513617

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

AFFILIATION: Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, The Netherlands.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Antimicrob Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice Related Publications

• A framework and methods for incorporating gender-related issues in wildlife risk assessment: gender-related differences in metal levels and other contaminants as a case study.
• A model for selecting bioindicators to monitor radionuclide concentrations using Amchitka Island in the Aleutians as a case study.
• Assessment and management of risk to wildlife from cadmium.
• Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
• Cancer stem cells and individualized therapy.
• Continuous-wave broadly tunable Cr(2+):ZnSe laser.
• Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
• Genomic and nongenomic effects of estrogen signaling in human endometrial cells: involvement of the growth factor receptor signaling downstream AKT pathway.
• Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
• Mixed effects modeling of weight change associated with placebo and pregabalin administration.
• Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention.
• Monoclonal antibodies to guinea pig interferon-gamma: Tools for cytokine detection and neutralization.
• Not Available
• Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
• Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
• Product update.
• Protective sustainability of ecosystems using Department of Energy buffer lands as a case study.
• Quantitative thin-layer chromatography of cobalamin complexes.
• Telomerase and its potential for therapeutic intervention.
• Telomerase in cancer diagnosis and therapy: a clinical perspective.
• The assessment of alexithymia in medical settings: implications for understanding and treating health problems.
• The effect on ecological systems of remediation to protect human health.
• Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
• Therapeutic implications of leukemic stem cell pathways.
• Treatment seeking for alcohol and drug use disorders by immigrants to the Netherlands: retrospective, population-based, cohort study.
• [Endothelioma as variety of tubular mesothelioma of the ovary.]
• [Horner's syndrome after fracture of the first rib]
• [New knowledge and experience with the urinary organs in pregnancy.]
• [Not Available.]
• [ON TRANSVERSE PRESENTATION.]